Does a cannabinoid product 'go bad' the same way food does?

Not exactly. Cannabinoid degradation is primarily a chemical process — oxidation, photolysis, and isomerisation — rather than microbial spoilage. The active constituents change into different chemical compounds rather than simply rotting. However, the carrier oil in oil-based products (such as MCT oil) can undergo rancidity, which is more analogous to food spoilage and produces recognisable sensory changes.

What does cannabinoid degradation actually produce?

The main degradation products documented in the pharmaceutical literature include cannabinol (CBN) from THC oxidation, and delta-8-THC or delta-9-THC from CBD isomerisation under acidic or thermal stress. Terpenes, if present, volatilise and are simply lost from the product. These are distinct chemical entities from the originals and are not pharmacologically interchangeable with them.

Why do some products say 'store below 25°C' rather than 'refrigerate'?

The storage condition stated on a label corresponds to the conditions under which the manufacturer's formal stability testing was conducted — typically 'long-term' testing at 25°C/60% relative humidity per ICH guidelines. Refrigeration (2–8°C) is used when the stability data requires it, or when the product is particularly sensitive to oxidation or microbial growth. Either way, the stated condition is a data-backed requirement, not an arbitrary suggestion.

Is there any difference in shelf stability between full-spectrum, broad-spectrum, and isolate products?

Potentially, yes, though the published literature doesn't give a definitive ranking. Full-spectrum preparations contain terpenes, which are volatile and can be lost through evaporation, changing the product's chemical composition over time. Isolate products lack these additional compounds but also lose any antioxidant contributions minor cannabinoids or polyphenols might provide. Broad-spectrum products sit somewhere between the two. All reputable products supplied through TGA-regulated channels should have formal stability data supporting their claimed shelf life regardless of spectrum.

Does Australian regulation require cannabinoid products to undergo stability testing?

Yes. Products registered on the ARTG, and those manufactured for supply through the Special Access Scheme or Authorised Prescriber pathway, must be manufactured under Good Manufacturing Practice (GMP) conditions. GMP requirements include formal stability testing — both real-time and accelerated — in line with ICH guidelines. This applies to cannabinoid products just as it does to other therapeutic goods regulated by the TGA.

Shelf Life and Storage of Cannabinoid Products

By Tom Whitfield · 30 May 2026 · 7 min read

The question nobody asks until it's too late

Roughly a third of the cannabinoid products I've tracked through literature reviews over the past few years carry a shelf-life claim somewhere on the label , but almost none of them explain what actually happens to the chemistry when those conditions aren't met. That gap bothers me, professionally.

This is a pharmacology and formulation question, not a clinical one. Understanding why cannabinoids degrade, and under what conditions that degradation accelerates, sits squarely in the domain of analytical chemistry and pharmaceutical science. So let's go there.

Cannabinoids are chemically unstable , that's just chemistry

Cannabidiol (CBD) and tetrahydrocannabinol (THC) are both terpenophenolic compounds. The phenolic ring and the relatively long aliphatic side-chain make them susceptible to oxidation, photolysis (breakdown triggered by light), and isomerisation at elevated temperatures. These are not exotic failure modes , they're standard organic chemistry.

A 2020 study published in the Journal of Pharmaceutical and Biomedical Analysis examined cannabinoid stability under accelerated stress conditions and found that CBD can convert to delta-9-THC and other isomers under acidic conditions and heat, while THC readily oxidises to cannabinol (CBN) when exposed to oxygen. CBN is itself a cannabinoid, but it represents a distinct chemical entity with different receptor-binding characteristics; it isn't simply "old THC." The distinction matters for pharmacokinetics and for understanding what a product actually contains at the time of use.

Light is the fast lane to degradation. Ultraviolet exposure accelerates photolysis markedly. That's why pharmaceutical-grade cannabinoid preparations are almost always packaged in amber glass or opaque containers, not for aesthetics, but because that's what the photostability science demands under ICH Q1B guidelines (the international stability testing standard applied to pharmaceutical products, including those listed on the Australian Register of Therapeutic Goods, or ARTG).

What degrades, and into what

The degradation chemistry is worth mapping out, even briefly. Raw cannabinoid acids, THCA and CBDA; decarboxylate under heat, converting to their neutral counterparts. That conversion is well understood and intentional during processing. But what happens afterwards, once the neutral cannabinoids are in a formulated product, is less often discussed.

THC oxidation proceeds primarily through an epoxidation of the double bond, eventually yielding CBN and several minor oxygenated products. CBD isomerisation under acidic or thermal stress can produce delta-8-THC and delta-9-THC, which are pharmacologically distinct. This is not hypothetical, it's been documented in product stability studies. There's also evidence that some of the more minor cannabinoids like cannabigerol (CBG) are similarly susceptible to oxidative degradation, though they've attracted less scrutiny simply because they appear in lower concentrations and have been studied for less time.

Terpenes are even more volatile than cannabinoids. Myrcene, limonene, linalool and beta-caryophyllene, all commonly present in full-spectrum preparations; have low boiling points and evaporate readily, particularly from poorly sealed containers or products stored in warm environments. If the terpene profile is part of the product's intended character (whether for sensory reasons or because of the theoretical entourage effect), terpene loss is a genuine formulation concern.

The carrier matrix changes everything

A cannabinoid doesn't exist in isolation in a finished product, it's dissolved or suspended in a carrier, and that carrier has its own stability profile. Oil-based formulations (medium-chain triglyceride oil is common) can undergo rancidity, particularly if exposed to heat and oxygen. Rancid carrier oil will change the sensory profile of a product well before the cannabinoid itself has fully degraded, which is one reason oxidative stability of the whole formulation matters, not just the active constituent.

Capsule-based preparations have a different profile again. The gelatin shell or hydroxypropyl methylcellulose of a hard capsule can absorb moisture, promoting microbial growth or physical breakdown of the capsule itself. Soft gels are generally better at protecting lipophilic actives from oxygen but can become brittle or fuse at elevated temperatures, a real consideration in Queensland summers, honestly, where a car glovebox is basically a small oven from November through March.

Topical formulations introduce emulsion stability into the equation: water activity, pH, preservative efficacy, and the potential for phase separation all vary with storage conditions. And inhaled flower products; still a significant category under the Special Access Scheme and Authorised Prescriber pathways, have their own drying and moisture dynamics. Too dry and the material becomes harsh; too moist and microbial growth becomes a concern.

What Good Manufacturing Practice requires

In Australia, therapeutic goods containing cannabinoids are regulated by the TGA. Products on the ARTG, and those supplied through the SAS or AP pathways, are manufactured under Good Manufacturing Practice (GMP) conditions. GMP mandates formal stability testing, real-time and accelerated; following ICH guidelines. This means manufacturers must demonstrate, with actual data, that a product meets its claimed specifications through to the stated expiry date under defined storage conditions.

The conditions that appear on a label ("store below 25°C, away from direct light, keep tightly sealed") aren't suggestions; they're the conditions under which the stability data was generated. Storing a product differently effectively voids the manufacturer's stability guarantee, though that's rarely spelled out plainly.

I'll say this plainly: I think the gap between what GMP stability testing requires and what actually gets communicated to the end-user is one of the more underappreciated problems in this space. The label exists; the explanation of what those conditions actually protect against, and what degradation looks like in practice, rarely does.

Practical storage chemistry, what the physics says

The Arrhenius equation; foundational in pharmaceutical shelf-life prediction, describes how reaction rates roughly double for every 10°C increase in temperature. A product stable at 15°C for 24 months might have an effective shelf life considerably shorter if stored at 30°C. Queensland ambient temperatures in summer routinely exceed 30°C indoors without air conditioning. That's not alarmism; it's kinetics.

Light exclusion matters more than many people expect. UV-A (315–400 nm) and UV-B (280–315 nm) are the primary photodegradants for cannabinoids. A product left on a sunny windowsill, even inside amber glass; will degrade faster than one stored in a dark cupboard. I've been reorganising my reference library shelves this past fortnight, pulling books away from the north-facing window because paper degrades the same way, and the chemistry is not so different.

Oxygen exclusion is the third variable. Some manufacturers use nitrogen-flushed packaging or oxygen-absorbing sachet inserts precisely because oxidation is so significant a degradation pathway for both cannabinoids and terpenes. Once a container is opened, oxygen exposure is inevitable, which is why multi-use containers with a realistic use-by-once-opened period are the more honest approach.

Freezing, incidentally, is generally fine for cannabinoid oils from a chemical stability standpoint, but repeated freeze-thaw cycling can affect emulsion stability and introduce physical changes that alter bioavailability. Refrigeration (2–8°C) is usually the practical sweet spot for extended storage of opened products, assuming the formulation tolerates it.

Broad-spectrum and isolate: does composition affect stability?

Broad-spectrum and isolate-based products have a somewhat different stability picture to full-spectrum preparations. The absence of other cannabinoids and terpenes removes some degradation pathways (terpene volatilisation, for instance) but also removes any antioxidant contributions that minor cannabinoids or polyphenolic compounds might provide. Whether that net effect is positive or negative likely depends on the specific formulation and its packaging, the published stability literature doesn't yet give a clean answer on this.

What I'd note is that any cannabinoid preparation reaching the Australian market through legitimate TGA-regulated channels will have stability data behind it. The challenge is that the product's subsequent handling; transport, retail storage, home storage, may not preserve the tested conditions. That's a supply-chain reality for temperature-sensitive therapeutics generally, not uniquely a cannabinoid problem. But it's worth understanding.

Sources

, Tom Whitfield, Health librarian; references & fact-checking

Common questions

Does a cannabinoid product 'go bad' the same way food does?: Not exactly. Cannabinoid degradation is primarily a chemical process — oxidation, photolysis, and isomerisation — rather than microbial spoilage. The active constituents change into different chemical compounds rather than simply rotting. However, the carrier oil in oil-based products (such as MCT oil) can undergo rancidity, which is more analogous to food spoilage and produces recognisable sensory changes.
What does cannabinoid degradation actually produce?: The main degradation products documented in the pharmaceutical literature include cannabinol (CBN) from THC oxidation, and delta-8-THC or delta-9-THC from CBD isomerisation under acidic or thermal stress. Terpenes, if present, volatilise and are simply lost from the product. These are distinct chemical entities from the originals and are not pharmacologically interchangeable with them.
Why do some products say 'store below 25°C' rather than 'refrigerate'?: The storage condition stated on a label corresponds to the conditions under which the manufacturer's formal stability testing was conducted — typically 'long-term' testing at 25°C/60% relative humidity per ICH guidelines. Refrigeration (2–8°C) is used when the stability data requires it, or when the product is particularly sensitive to oxidation or microbial growth. Either way, the stated condition is a data-backed requirement, not an arbitrary suggestion.
Is there any difference in shelf stability between full-spectrum, broad-spectrum, and isolate products?: Potentially, yes, though the published literature doesn't give a definitive ranking. Full-spectrum preparations contain terpenes, which are volatile and can be lost through evaporation, changing the product's chemical composition over time. Isolate products lack these additional compounds but also lose any antioxidant contributions minor cannabinoids or polyphenols might provide. Broad-spectrum products sit somewhere between the two. All reputable products supplied through TGA-regulated channels should have formal stability data supporting their claimed shelf life regardless of spectrum.
Does Australian regulation require cannabinoid products to undergo stability testing?: Yes. Products registered on the ARTG, and those manufactured for supply through the Special Access Scheme or Authorised Prescriber pathway, must be manufactured under Good Manufacturing Practice (GMP) conditions. GMP requirements include formal stability testing — both real-time and accelerated — in line with ICH guidelines. This applies to cannabinoid products just as it does to other therapeutic goods regulated by the TGA.